- Home
- TVGN vs NTRB Comparison
TVGN vs NTRB Comparison
Compare TVGN & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | NTRB |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 71.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TVGN | NTRB |
|---|---|---|
| Price | $0.40 | $4.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.4M | 23.4K |
| Earning Date | 11-14-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,278,321.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $0.38 | $3.72 |
| 52 Week High | $1.92 | $11.78 |
Technical Indicators
Market Signals| Indicator | TVGN | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 42.53 |
| Support Level | $0.39 | $4.60 |
| Resistance Level | $0.47 | $5.45 |
| Average True Range (ATR) | 0.04 | 0.37 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 20.37 | 54.82 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.